CA
HAE icon

Clearstead Advisors’s Haemonetics HAE Stock Holding History

Clearstead Advisors’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.28K Buy
97
+50
+106% +$3.21K ﹤0.01% 2083
2026
Q1 		$2.65K Sell
47
-914
-95% -$59.5K ﹤0.01% 1846
2025
Q4 		$77K Buy
961
+135
+16% +$9.07K ﹤0.01% 1209
2025
Q3 		$40.3K Sell
826
-678
-45% -$42K ﹤0.01% 1351
2025
Q2 		$112K Buy
1,504
+236
+19% +$15.6K ﹤0.01% 1035
2025
Q1 		$80.6K Sell
1,268
-109
-8% -$7.41K ﹤0.01% 1040
2024
Q4 		$108K Sell
1,377
-27
-2% -$2.17K ﹤0.01% 1011
2024
Q3 		$113K Buy
1,404
+1,339
+2,060% +$108K ﹤0.01% 1001
2024
Q2 		$5.38K Buy
+65
New +$5.72K ﹤0.01% 1676
2021
Q4 		– Sell
-133
Closed -$9K – 1341
2021
Q3 		$9K Buy
+133
New +$8.39K ﹤0.01% 955

Other funds holding HAE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Clearstead Advisors's HAE Position: Q2 2026 in Review

Clearstead Advisors increased its Haemonetics (HAE) stake by 106% in Q2 2026, buying an estimated $3.21K and bringing the position to 97 shares worth $7.28K. The position accounts for ﹤0.01% of the portfolio, ranked #2083.

Clearstead Advisors first reported a position in HAE in Q3 2021 and has held it in 10 quarters since. The position peaked at $113K in Q3 2024. 329 funds tracked by Wall St. Rank hold HAE as of Q2 2026.

  • Clearstead Advisors held 97 shares of Haemonetics worth $7.28K as of Q2 2026.
  • Clearstead Advisors bought 50 Haemonetics shares in Q2 2026, an estimated $3.21K.
  • Haemonetics made up ﹤0.01% of Clearstead Advisors's portfolio in Q2 2026, its #2083 holding.
  • Clearstead Advisors first reported a position in Haemonetics in Q3 2021 and has held it in 10 quarters since.
  • Clearstead Advisors's Haemonetics position peaked at $113K in Q3 2024.
  • 329 funds tracked by Wall St. Rank held Haemonetics as of Q2 2026.

Based on Clearstead Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.